Alzheimer’s disease is associated with prostate cancer: a population-based study

Herng-Ching Lin¹,², Li-Ting Kao²,³,*, Shiu-Dong Chung⁴, Chung-Chien Huang¹,*, Ben-Chang Shia⁵,⁶,* and Chao-Yuan Huang⁶,⁷,*

¹School of Health Care Administration, Taipei Medical University, Taipei, Taiwan
²Sleep Research Center, Taipei Medical University Hospital, Taipei, Taiwan
³Graduate Institute of Life Science, National Defense Medical Center, Taipei, Taiwan
⁴Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Banciao, New Taipei City, Taiwan
⁵Big Data Research Center, Taipei Medical University, Taipei, Taiwan
⁶Department of Urology, National Taiwan University Hospital, College of Medicine National Taiwan University, Taipei, Taiwan
⁷School of Public Health, Taipei Medical University Hospital, Taipei, Taiwan

*These authors contributions equally to this work

Correspondence to: Chao-Yuan Huang, email: cyh540909@gmail.com

Keywords: Alzheimer’s disease; prostate cancer; epidemiology

Received: July 25, 2017  Accepted: January 04, 2018  Published: January 10, 2018

ABSTRACT

Alzheimer’s disease and cancer are increasingly prevalent with advancing age. However, the association between Alzheimer’s disease and prostate cancer remains unclear. The aim of this study was to examine the relationship between prior Alzheimer’s disease and subsequent prostate cancer using a population-based dataset in Taiwan. Data for this study were sourced from the Taiwan Longitudinal Health Insurance Database 2005. This case-control study included 2101 prostate cancer patients as cases and 6303 matched controls. We used conditional logistic regression analyses to calculate the odds ratio (OR) and corresponding 95% confidence interval (CI) for Alzheimer’s disease between prostate cancer patients and controls. We found that of the 8404 sampled patients, 128 (1.5%) had been diagnosed with Alzheimer’s disease prior to the index date. A Chi-squared test showed that there was a significant difference in the prevalences of prior Alzheimer’s disease between prostate cancer patients and controls (2.1% vs. 1.3%, p < 0.001). The conditional logistic regression analysis showed that the OR of prior Alzheimer’s disease for prostate cancer patients was 1.53 (95% CI: 1.06~2.21) compared to controls. Furthermore, the OR of prior Alzheimer’s disease for prostate cancer patients was 1.52 (95% CI: 1.04~2.22) compared to controls after adjusting for hypertension, diabetes, coronary heart disease, hyperlipidemia, obesity, prostatitis, gonorrhea or chlamydia infection, testitis or epididymitis, and alcohol abuse/alcohol dependency syndrome. This study revealed an association between prior Alzheimer’s disease and prostate cancer. We suggest that clinicians be alert to the increased risk of prostate cancer when caring for elderly individuals with Alzheimer’s disease.

INTRODUCTION

Alzheimer’s disease (AD), the fifth leading cause of death in adults over 65 years of age in the United States, is one of the most prevalent neurodegenerative disorders worldwide [1]. In the United States, an estimated 5.2 million individuals over 65 years of age had AD in 2012 [2], and the number of people who develop AD is expected to increase by almost triple, to 13.5 million by 2050 [3, 4]. AD and cancer are increasingly prevalent with advancing age,
and the probability of the co-occurrence of both AD and cancer in the same patient also rises with increasing age [5].

Prostate cancer (PC) is the second major cause of cancer-related mortality among older males in Western countries, and androgen deprivation therapy (ADT) is the first-line treatment for patients with PC [6, 7]. However, only two prior retrospective cohort studies explored the association between dementia and PC [4, 8], but those studies showed contradictory results. In addition, some studies further examined the association between AD or dementia and the use of ADT for treating PC [9–13]. However, their findings on the association between the use of ADT and dementia were inconsistent, and some methodological limitations were observed in those studies, such as small sample sizes, absence of consideration of exposure lag periods, and short follow-up periods. Furthermore, the majority of the above studies focused on the association between PC and the subsequent risk of dementia, and very few studies attempted to investigate the association between prior dementia or AD and PC. The lack of such studies prevents researchers from understanding the underlying mechanisms between these two medical conditions.

Therefore, the aim of this study was to examine the relationship between prior AD and subsequent PC using a population-based dataset in Taiwan.

RESULTS

We found that of the 8404 sampled patients, the mean age was 74.1 ± 9.5 (± standard deviation) years. After matching for age, monthly income, geographical location, urbanization level of the patient’s residence, and index date, Table 1 shows that there were significant differences in hyperlipidemia ($p < 0.001$), obesity ($p = 0.008$), prostatitis ($p < 0.001$), and testitis or epididymitis ($p = 0.043$) between PC patients and controls.

Table 2 shows the prevalences of prior AD between PC patients and controls. Of the 8404 sampled patients, 128 (1.5%) had been diagnosed with AD prior to the index date. A Chi-squared test showed that there was a significant difference in the prevalences of prior AD between PC patients and controls (2.1% vs. 1.3%, $p < 0.001$).

The OR and its corresponding 95% CI for having been previously diagnosed with AD between PC patients and controls are presented in Table 3. The conditional logistic regression (conditioned on age, monthly income, geographical location, urbanization level of the patient’s residence, and index date) showed that the OR of prior AD for PC patients was 1.53 (95% CI: 1.06–2.21) compared to controls. Furthermore, the OR of prior AD for PC patients was 1.52 (95% CI: 1.04–2.22) compared to controls after adjusting for hypertension, diabetes, coronary heart disease, hyperlipidemia, obesity, prostatitis, gonorrhea or chlamydia infection, testitis or epididymitis, and alcohol abuse/alcohol dependency syndrome. We also found that PC was positively and significantly associated with obesity (adjusted OR = 1.77, 95% CI = 1.00–3.14), hyperlipidemia (adjusted OR = 1.21, 95% CI = 1.09–1.35), and prostatitis (adjusted OR = 2.79, 95% CI = 2.36–3.30). However, PC was negatively and significantly associated with diabetes (adjusted OR = 0.88, 95% CI = 0.79–0.99).

DISCUSSION

This population-based case-control study found an association between prior AD and PC. To the best of our knowledge, this is the first study to report an association between AD and PC. We found that patients with PC were 1.53-times more likely than controls to have had a previous diagnosis of AD. Even after adjusting for medical comorbidities, patients with PC were still at 1.52-times greater risk than comparison subjects for having a diagnosis of prior AD.

Two previous studies reported on the association between dementia and PC [5, 8]. One retrospective cohort study by Raji et al. included 106,061 patients aged 68 years or older with breast, colon, or PC in the United State and evaluated the risks of mortality from cancer and non-cancer causes, stratified by the presence or absence of preexisting dementia [5]. They found that a dementia diagnosis was associated with increased odds of being diagnosed at an unknown stage of PC. Another retrospective cohort study by Lin et al. included 3282 subjects with dementia and investigated the risk of cancers occurring after a diagnosis of dementia [8]. Those authors found that the adjusted HR for PC among dementia patients was 0.44 (95% CI = 0.20–0.98) during a 7-year follow-up period compared to controls. However, that study did not take potential confounders such as prostatitis, and gonorrhea or chlamydia infection into consideration in their study.

The association of AD and PC is supported by some plausible biologic mechanisms including through abnormal deposits of proteins [20, 21], neuronal cell death [5, 13, 22], and oxidative stress [23, 24]. First, the amyloid precursor protein (APP) is a type I transmembrane protein that produces various proteolytic products due to alternative splicing [25]. Among its products, β-amyloid is generated by sequential and abnormal cleavage of the APP in the central nervous system, and was implicated in the development of AD [26, 27]. Previous studies also showed that the APP is a primary androgen-responsive gene that promotes the growth of PC cells, and that its high immunoreactivity is connected with poor prognoses in patients with PC [27, 28]. Therefore, sequential and abnormal cleavage of the APP might be one potential explanation for the association between AD and PC.

The second plausible explanation might be neuronal cell death. Neuronal cell death is one of the pathognomonic neurofibrillary tangle formations in AD [13]. Graham et al. also showed that these protein posttranslational modifications result in destabilization of the cytoskeleton,
which in turn results in observed neuronal cell death [22]. Moreover, cancer is characterized by uncontrolled cell proliferation [8]. Consequently, neuronal cell death caused by a malfunction in cell growth regulation might be one potential mechanism for the association between AD and PC. Moreover, oxidative stress was shown to play an important role in the pathophysiology of neuron degeneration and death in AD [29, 30]. In addition, induction of oxidative stress from ADT in PC patients could produce reactivation of androgen receptor signaling in a hormone-refractory manner [31, 32]. Thus, oxidative stress might be implicated in the association between AD and PC. Furthermore, the action of acetylcholinesterase inhibitors in patients with AD is

Table 1: Demographic characteristics of patients with prostate cancer and controls in Taiwan (n = 8404)

| Variable                        | Patients with prostate cancer (N = 2101) | Controls (N = 6303) | p value |
|---------------------------------|-----------------------------------------|---------------------|---------|
|                                 | Total no. | Percent (%) | Total no. | Percent (%) |         |
| Age, mean (SD), years           | 74.1 (9.5) |            | 74.1 (9.5) |            | >0.999  |
| Urbanization level              |           |            |           |            | >0.999  |
| 1 (most urbanized)              | 640       | 30.5       | 1920      | 30.5       |         |
| 2                               | 607       | 28.9       | 1821      | 28.9       |         |
| 3                               | 291       | 23.8       | 873       | 23.8       |         |
| 4                               | 313       | 14.9       | 939       | 14.9       |         |
| 5 (least urbanized)             | 250       | 11.9       | 750       | 11.9       |         |
| Monthly income                  |           |            |           |            | >0.999  |
| ≤NT15,840                       | 1212      | 57.7       | 3636      | 57.7       |         |
| NT$15,841–25,000                | 601       | 28.6       | 1803      | 28.6       |         |
| ≥NT$25,001                      | 288       | 13.7       | 864       | 13.7       |         |
| Geographic region               |           |            |           |            | >0.999  |
| Northern                        | 1059      | 50.4       | 3177      | 50.4       |         |
| Central                         | 497       | 23.7       | 1491      | 23.7       |         |
| Southern                        | 497       | 23.7       | 1491      | 23.7       |         |
| Eastern                         | 48        | 2.2        | 144       | 2.2        |         |
| Obesity                         | 21        | 1.0        | 30        | 0.5        | 0.008   |
| Hypertension                    | 1547      | 73.6       | 4677      | 74.2       | 0.605   |
| Diabetes mellitus               | 675       | 32.1       | 2073      | 32.9       | 0.519   |
| Testitis or epididymitis        | 47        | 2.2        | 99        | 1.6        | 0.043   |
| Gonorrhea or chlamydia infection| 31        | 1.5        | 67        | 1.1        | 0.127   |
| Hyperlipidemia                  | 945       | 45.0       | 2527      | 40.1       | <0.001  |
| Alcohol abuse/alcohol dependence syndrome | 4 | 0.2 | 20 | 0.3 | 0.345 |
| Prostatitis                     | 295       | 14.0       | 333       | 5.3        | <0.001  |

The average exchange rate in 2014 was US$1.00≈New Taiwan (NT)$29.

Table 2: Prevalence for prior Alzheimer’s disease among sampled subjects

| Presence of prior Alzheimer’s disease | Total (N = 8404) | Patients with prostate cancer (N = 2101) | Controls (n = 6303) |
|--------------------------------------|-----------------|------------------------------------------|---------------------|
|                                      | n, Percent (%)  | n, Percent (%)                          | n, Percent (%)      |
| Yes                                  | 128          | 1.5                          | 43            | 2.1                          | 85          | 1.3                      |
| No                                   | 8276       | 94.5                         | 2058           | 97.9                         | 6218       | 98.7                      |

Notes: There was a significant association between prostate cancer and prior Alzheimer’s disease (p < 0.001).
considered to be a potential mechanism underlying AD-associated tumorigenesis. To date, the acetylcholinesterase inhibitors are the common managements for AD [33]. Nevertheless, increasing biological evidences indicated that acetylcholinesterase activity in cancer is decreased, which may further contribute to cancer cell proliferation [34, 35]. Therefore, downregulated acetylcholinesterase activity in AD patients receiving acetylcholinesterase inhibitors might be one potential elucidation for the relationship between AD and PC.

This study has a number of strengths. The use of a longitudinal population-based database can decrease selection bias and avoid recall bias which often occur in case-control studies. Moreover, over 98% of Taiwan’s residents are of Chinese Han ethnicity, so the homogenous population may exempt our study from potential confounding by race. Nevertheless, this study possesses limitations that warrant consideration. First, studies that rely on diagnostic codes for an AD diagnosis are susceptible to misclassification [36, 37]. Detailed medical records, including biochemical tests, Mini-Mental State Examination (MMSE) scores, and medical imaging were not available in the database. However, we only included those AD cases who had received prescriptions of AChEIs, which needs to be approved by a committee including neurologists or psychiatrists, in order to increase the accuracy of the clinical diagnosis of AD. Second, the database also provides no lifestyle information or laboratory records, including inflammatory biomarkers, family history, and genetic factors. These factors might affect cognitive function and impact the association between prior AD and subsequent PC [38, 39]. Third, most patients involved in this case-control study were of Chinese Han ethnicity. Therefore, the findings in this study might not be generalized to other ethnic groups with high PC prevalence. Last, the current study design does not permit an unequivocal inference of a causal relationship between AD and PC.

Despite these limitations, this population-based case-control study revealed an association between AD and PC. We suggest that clinicians be alert to the increased risk of PC when caring for elderly individuals with AD. Further large-scale epidemiological, experimental, or pathological studies are necessary to determine the mechanisms underlying this association between prior AD and subsequent PC.

### METHODS

#### Database

The data for this study were from the Longitudinal Health Insurance Database 2005 (LHID2005). The LHID2005, which is derived from medical claims records of the Taiwan National Health Insurance (NHI) program, consists of medical claims and registration files for 1,000,000 enrollees under the Taiwan NHI program. The Taiwan National Health Institute randomly selected these 1,000,000 enrollees from all enrollees (25.68 million) listed in the 2005 Registry of Beneficiaries. The LHID2005, which is open to researchers in Taiwan, offers an excellent opportunity to clarify the relationship between AD and PC using a population-based study.

This study was exempt from full review by the Institutional Review Board of Taipei Medical University (TMU-JIRB N201612023) since the LHID2005 consists of de-identified secondary data released without restriction to researchers for research purposes.

#### Study sample

This case-control study comprised cases (patients with PC) and matched controls. As for the selection of cases, 2154 patients with a first-time diagnosis of PC (ICD-9-CM code 185) during an ambulatory care
visit between January 2007 and December 2013 were identified. We excluded 53 patients under 50 years of age because of a very low prevalence of PC and AD in this age group. As a result, 2101 PC patients were included as cases. We further assigned the first claim date with a diagnosis of PC as the index date for cases.

We selected male controls from the remaining male beneficiaries of the LHID2005. We initially assured that none of the selected controls had ever received a diagnosis of PC in any claim. We then selected three controls (n = 6303) per case matched by age, monthly income (NTS0–15,840, NTS15,841–25,000, ≥NTS25,001; the average exchange rate in 2008 was US$1.00=New Taiwan (NT)$29), geographical location (northern, central, southern, and eastern), urbanization level of the patient’s residence, and year of the index date. The year of the index date for cases was the year in which they received the first claim date with a diagnosis of PC. For controls, the year of the index date for controls was the matched year in which the controls had at least one episode of utilization of ambulatory care. Furthermore, we defined the date of first utilization of ambulatory care occurring in the index year as the index date for controls.

Exposure assessment

This study identified AD cases based on ICD-9-CM codes 290 and 331.0. In addition, we only included those AD cases who had received prescriptions of acetylcholinesterase inhibitors (AChEIs) in order to increase the validity of the AD diagnoses. In Taiwan, prescribing AChEIs for patients with AD needs to be approved by a committee including neurologists or psychiatrists. This committee evaluates whether those patients are entitled for reimbursement for AChEIs according to patients’ clinical records, cognitive function, biochemistry tests, and diagnostic imaging. Furthermore, we only included those AD cases who had received at least one AD diagnoses before the index date.

Statistical analysis

The SAS system for Windows (vers. 8.2, SAS Institute, Cary, NC) was used to perform all statistical analyses in this study. Chi-squared tests were carried out to explore differences in sociodemographic characteristics, hypertension, diabetes, hyperlipidemia, prostatitis, gonorrhea or chlamydia infection, testitis or epididymitis, obesity, and alcohol abuse/alcohol dependence syndrome between PC patients and controls. In addition, this study used ICD-9-CM codes to identify those cases with obesity (ICD-9-CM codes 278) and alcohol abuse/alcohol dependence syndrome (ICD-9-CM codes 291.1, 291.2, 291.5, 291.8, 291.9, 303.90–303.93, 305.00–305.03, V113). We then used conditional logistic regression analyses (conditioned on age, monthly income, geographical location, urbanization level of the patient’s residence, and index date) to calculate the odds ratio (OR) and the corresponding 95% confidence interval (CI) for AD between PC patients and controls. Additionally, the medical comorbidities, such as hypertension, diabetes, hyperlipidemia, prostatitis, gonorrhea or chlamydia infection, testitis or epididymitis, obesity, and alcohol abuse/alcohol dependence syndrome, were considered in the adjustment models in this study, because they were all potential confounders that might affect the association between AD and PC [14–19]. We used the conventional p ≤ 0.05 to assess statistical significance.

CONFLICTS OF INTEREST

There is no conflicts of interests to disclose.

FUNDING

None.

REFERENCES

1. Alzheimer’s Association. 2016 Alzheimer’s Disease facts and figures. Alzheimers Dement. 2016; 12:459–509.

2. Jhan JH, Yang YH, Chang YH, Guu SJ, Tsai CC. Hormone therapy for Prostate Cancer increases the risk of Alzheimer’s Disease: a nationwide 4-year longitudinal cohort study. Aging Male. 2017; 20:33–38.

3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007; 3:186–191.

4. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Olstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Willis RJ, Wallace RB. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007; 29:125–132.

5. Raji MA, Kuo YF, Freeman JL, Goodwin JS. Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or Prostate Cancer: implications for cancer care. Arch Intern Med. 2008; 168:2033–2040.

6. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Toceilla J, Pfeffer JR, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360:103–106.

7. Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012; 61:11–25.

8. Lin HL, Lin HC, Tseng YF, Chen SC, Hsu CY. Inverse Association Between Cancer and Dementia: A
Population-based Registry Study in Taiwan. Alzheimer Dis Assoc Disord. 2016; 30:118–22.

9. Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, Shah NH. Androgen Deprivation Therapy and Future Alzheimer’s Disease Risk. J Clin Oncol. 2016; 34:566–571.

10. Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association Between Androgen Deprivation Therapy and Risk of Dementia. JAMA Oncol. 2017; 3:49–55.

11. Chung SD, Lin HC, Tsai MC, Kao LT, Huang CY, Chen KC. Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with Prostate Cancer. Andrology. 2016; 4:481–485.

12. Kao LT, Lin HC, Chung SD, Huang CY. No increased risk of dementia in patients receiving androgen deprivation therapy for Prostate Cancer: a 5-year follow-up study. Asian J Androl. Asian J Androl. 2017; 19:414–417.

13. Nead KT, Sinha S, Nguyen PL. Prostate Cancer Androgen deprivation therapy for Prostate Cancer and dementia risk: a systematic review and meta-analysis. Prosttic Dis. 2017.

14. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013; 63:800–809.

15. Blanc-Lapierrre A, Spence A, Karakiewicz PI, Aprikian A, Saad F, Parent ME. Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada. BMC Public Health. 2015; 15:913.

16. Boehm K, Valdivieso R, Meskawi M, Larcher A, Schifffmann J, Sun M, Graefen M, Saad F, Parent ME, Karakiewicz PI. Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case-control study. World J Urol. 2016; 34:425–430.

17. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002; 13:72–79.

18. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002; 60:78–83.

19. Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer. 2016; 16:845.

20. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet. 2011; 377:1019–1031.

21. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer’s disease. Lancet. 2016; 388:505–517.

22. Graham WV, Bonito-Oliva A Sakmar TP. Update on Alzheimer's Disease Therapy and Prevention Strategies. Annu Rev Med. 2017; 68:413–430.

23. Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, Yee M, Crowley J, Schmitt FA. Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADvISE). JAMA Neurol. 2017; 74:567–573.

24. Lee JH, Kang M, Wang H, Naik G, Mobley JA, Sonpavde G, Garvey WT, Darley-Usmar VM, Ponnazhasan G. Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress. FASEB J. 2017; 31:1608–1619.

25. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997; 77:1081–1132.

26. Hansel DE, Rahman A, Wehner S, Herzog V, Yeo CJ, Maitra A. Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation. Cancer Res. 2003; 63:7032–7037.

27. Miyazaki T, Ikeda K, Horie-Inoue K, Inoue S. Amyloid precursor protein regulates migration and metalloproteinase gene expression in prostate cancer cells. Biochem Biophys Res Commun. 2014; 452:828–833.

28. Takayama K, Tsutsuami S, Suzuki T, Horie-Inoue K, Ikeda K, Kaneshiro K, Fujimura T, Kumagai J, Urano T, Sakaki Y, Shirahige K, Sasano H, Takahashi S, et al. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res. 2009; 69:137–42.

29. Viña J, Lloret A, Ortí R, Alonso D. Molecular bases of the treatment of Alzheimer’s disease with antioxidants: prevention of oxidative stress. Mol Aspects Med. 2004; 25:117–123.

30. Sano M, Ernesto C, Thomas RG, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997; 336:1216–1222.

31. Shiota M, Yokomizo A, Naito S. Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocr Relat Cancer. 2016; 23:117–130.

32. Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of prostate cancer cells. Cancer Res. 2009; 69:137–42.

33. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of acetylcholinesterase activity and the composition of enzyme forms in axillary lymph nodes. Breast Cancer Res Treat. 2003; 80:105–114.
36. Snowden JS, Thompson JC, Stopford CL, Richardson AM, Gerhard A, Neary D, Mann DM. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinico-pathological relationships. Brain. 2011; 134:2478–2492.

37. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol. 2012; 71:266–273.

38. Durazzo TC, Mattsson N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. Alzheimers Dement. 2014;10:S122–S145.

39. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Broserson F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14:388–405.